These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 27906698)

  • 21. Benralizumab for the treatment of asthma.
    Saco TV; Pepper AN; Lockey RF
    Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is new in antiimmunoglobulin E asthma therapy.
    Berger WE
    Allergy Asthma Proc; 2005; 26(6):428-34. PubMed ID: 16541964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY; Sur S; Grant JA; Tripple JW
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab in the Therapy of Pediatric Asthma.
    Poddighe D; Brambilla I; Licari A; Marseglia GL
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):103-109. PubMed ID: 29714140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
    Walsh GM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibody therapy in sinonasal disease.
    Chiarella SE; Sy H; Peters AT
    Am J Rhinol Allergy; 2017 Mar; 31(2):93-95. PubMed ID: 28281440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?
    Ko E; Chehade M
    Clin Rev Allergy Immunol; 2018 Oct; 55(2):205-216. PubMed ID: 29372536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
    Akenroye A; Nopsopon T; Hacker JJ; Laidlaw TM
    Sci Rep; 2024 May; 14(1):10404. PubMed ID: 38710930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
    Rivero A; Liang J
    Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-step algorithm for biological therapy targeted IgE and IL-5 in severe asthma.
    Oishi K; Matsunaga K
    Immun Inflamm Dis; 2018 Sep; 6(3):374-376. PubMed ID: 30088345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.
    Eskian M; Khorasanizadeh M; Assa'ad AH; Rezaei N
    Clin Rev Allergy Immunol; 2018 Aug; 55(1):88-98. PubMed ID: 29234969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.